Mark A. Socinski, MD,

Articles

Final Thoughts on Effective Therapy and Financial Toxicity

September 20th 2021

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

Innovation of Therapies vs Disruptive Pricing

September 20th 2021

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity

September 13th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.

Review of GEMSTONE-301 and -302 Data

September 13th 2021

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Pharmacoeconomic Considerations for Immunotherapy

September 7th 2021

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers

August 30th 2021

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Place for EGFR Agents and Comparison of Costs

August 30th 2021

A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Dr. Socinski on the Role of Immunotherapy in PD-L1–Negative Lung Cancer

February 6th 2021

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

March 31st 2020

Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.

Dr. Socinski on New Applications of Immunotherapy in NSCLC

April 16th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

March 26th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Dr. Socinski on Current State of Treatment in NSCLC

February 22nd 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Dr. Socinski on Immunotherapy Approaches in Squamous NSCLC

January 30th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Dr. Socinski on Milestone of Immunotherapy in Lung Cancer

March 6th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).